Hikma Acts to Ease Critical Shortage of Pain Medications Needed by US Hospitals and Their Patients
July 18 2018 - 7:00AM
Business Wire
Leading Generic Pharmaceutical Company Increases Manufacturing
Capacity to Produce and Release Significant Quantities of Scarce
Medicines
Hikma Pharmaceuticals PLC (the Hikma Group) (LSE: HIK) (NASDAQ
Dubai: HIK) (OTC: HKMPY), the multinational generic pharmaceutical
company, announced today that its US business has begun releasing
significant quantities of hydromorphone to US hospital customers to
help ease a current shortage of injectable opioids used to treat
patients.
In response to this shortage, Hikma released more than five
million hydromorphone 2ml vials to US hospitals during June, and
expects to release another three million vials during July. The
current US hospital shortage of injectable opioids used for patient
pain management occurred when a significant supplier to the US
market temporarily ceased manufacturing.
Daniel Motto, Executive Vice President of Hikma’s US Injectables
Division, commented: “We continue to prioritize the manufacture of
opioid products affected by this shortage including fentanyl,
meperidine, morphine and hydromorphone to provide hospitals and
doctors with the medicines they need to best treat their
patients.”
“We have the capacity in our FDA-inspected manufacturing
facility in Cherry Hill, New Jersey for all CII opioid injectable
products, and believe we can now address the current shortage of
these vital and urgently needed medications, pending increased
quota allowances from the US Drug Enforcement Administration.”
For more information about our US business, please visit
www.hikma.com/us
-- ENDS --
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
40 years, we’ve been creating high-quality medicines and making
them accessible to the people who need them. We're a global company
with a local presence across the United States (US), the Middle
East and North Africa (MENA) and Europe, and we use our unique
insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,500 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner in
the MENA region, and through our venture capital arm, are helping
bring innovative health technologies to people around the world.
For more information, please visit www.hikma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180718005345/en/
Hikma Pharmaceuticals PLCSteven H. WeissSenior Director,
US Communications and Public Affairs+1 732 542 1191/ +1 917 374
2024orBrooke ClarkeVice President Corporate Affairs+44 (0)20 7399
2795/ +44 (0)7970 338 250orVirginia SpringInvestor Relations
Manager+44 (0)20 3892 4389/ +44 7973 679502orFTI
ConsultingBen Atwell/Brett Pollard/Andrew Ward+44 (0)20 3727
1000
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2023 to Apr 2024